Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Eva Marchese
The 3 Business Models That Will Attract Buyers To My High-Cost Medical Device
By Eva Marchese and Lorenzo D’Angelo, CRA The global medical devices market is projected to grow at 4.4% CAGR until 2025.1 But large medical devices with high initial procurement costs are experiencing growing pains. Customers are now scrutinizing prices as transparency of the procurement process increases and hospital consolidation weakens manufacturers’ negotiating positions.
Impact of COVID-19 Pandemic on Funding and Reimbursement of Pharmaceuticals and Vaccines
Most European countries have experienced more than one wave of COVID-19 infections. Lockdown and social distancing measures implemented to control the infection rates have resulted in a significant contraction in European economies. It is expected that several months or even years will be required for economies to regain their pre-pandemic levels. COVID-19 vaccines have emerged as a key tool against the pandemic with several candidates achieving emergency or conditional approval.
How innovative business models can help sell high-cost medical devices
Eva Marchese, Lorenzo D’Angelo, and Amy Niu from the global consulting firm CRA explain how indication expansions, equipment financing, and innovative pricing can help overcome challenges in selling high-cost medical devices when the market and account requirements are understood.
Digital Health Technologies: The Evolving Landscape Of Reimbursement & 4 Strategies To Consider
By Eva Marchese, Lev Gerlovin, Lorenzo D’Angelo, and Anthony Barron, Life Sciences Practice, CRA The use of digital health technologies (DHTs), ranging from devices and apps to cloud-based services and artificial intelligence platforms, has accelerated rapidly in recent years, especially in response to the COVID-19 pandemic.
Overcoming Funding Challenges For Innovative Medtech In Germany: Learnings From The NUB Process
By Eva Marchese, Lorenzo D’Angelo, Anthony Barron, and Oriol Viader-Llargués, CRA Germany is the leading medtech market in Europe, with a 22% market share. While funding for high-cost innovative medtech in Germany has evolved in recent years, there are still many challenges in securing reimbursement even as demand for these technologies surges.
Assessing the impact of disease prevalence on access and pricing of rare disease drugs in England
The study focused on answering three key questions: 1. Is disease rarity a predictor of reimbursement? 2. Is there a relationship between disease rarity and the cost of treatment? 3. Are drugs for rare diseases disproportionately subject to commercial agreements? Is disease rarity a predictor of reimbursement?
Sanofi Steps in to Help Pfizer Vaccine Production
The staggering and unexpected global shortage of COVID-19 vaccines has left a healthcare delivery system devastated. U.S. pharma giant Pfizer, and its German partner BioNTech, have been quickly overwhelmed by sheer global demand. No vaccine has ever been developed or distributed so quickly. To the rescue, several drug companies are collaborating on manufacturing and distributing Pfizer’s two-dose vaccine to help reach millions more people.
How to Sell the COVID-19 Vaccine
One COVID-19 vaccine just received emergency use authorization and another is pending. the next important task will be getting the public vaccinated. To say its release will be fraught is an understatement.
Can “Risk-Sharing” Agreements Enable Fast Access to COVID-19 Vaccines?
As the global COVID-19 pandemic has progressed, so too have efforts to develop, manufacture, and secure the supply of potentially effective vaccines. At the time of writing, more than 45 vaccine candidates have entered clinical development, with several front-runners including Pfizer-BioNTech well positioned to begin delivering vaccines in the near future. But procuring bodies such as governments and supranational organizations face many challenges in getting vaccines in the hands of patients.
Challenges in optimizing EU market access for immuno-oncology therapies
With CAR-T therapies closer than ever to delivering on their promise but still facing significant obstacles,… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Eva
Contact Eva, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack